The landscape of oncology is shifting from a focus on immediate treatment to a lifelong commitment to genetic awareness. Ivan Kairatov, a prominent Biopharma expert with a distinguished career in research and development, has spent years navigating the intersection of technology and patient care. His insights into how we can utilize retrospective data to protect cancer survivors offer a new perspective on precision medicine. This conversation explores the logistical hurdles of re-engaging past patients, the success of decentralized testing models like BRCA-DIRECT, and the vital role of national registries in ensuring that no survivor is left behind as genetic technology evolves.
The reality for many cancer survivors is that the technology we use today simply wasn’t an option during their initial diagnosis. How do you identify these individuals within existing health records, and what are the most effective ways to re-engage them for testing years later?
The process begins by tapping into the immense power of national cancer registrations and centralized genetic laboratory data. We specifically looked at the UK-only Retrospective Genetic Testing Programme, which targeted survivors who met current eligibility criteria—such as those with triple-negative or young-onset breast cancer—but had never been offered a test. In our pilot phase, we identified 3,525 patients diagnosed between 2015 and 2018 and reached out to them directly. The most effective engagement strategy was providing a simple, home-based saliva kit that removed the physical and emotional burden of returning to a hospital setting for a blood draw. It is incredibly moving to see that 43.7% of these individuals accepted the invitation, showing a clear hunger for this missing piece of their medical history.
In recent screening programs, roughly 9% of breast cancer survivors and 10% of ovarian cancer survivors tested positive for inherited variants. How do home-based saliva tests facilitate this discovery, and what specific medical interventions are triggered once a variant is found?
Home-based saliva tests act as a bridge, allowing us to gather high-quality genetic material without the logistical friction of traditional clinic visits. Our data showed that 8.6% of breast cancer survivors and 10.1% of ovarian cancer survivors carried a germline pathogenic variant that they were previously unaware of. Once a variant is identified, it triggers a cascade of personalized follow-up care that can range from more frequent MRI screenings to risk-reducing surgeries. Beyond the patient, this discovery is a critical sensory moment for families, as it allows us to inform at-risk relatives who can then pursue their own preventative measures. This transformation from a retrospective look at a past diagnosis to a proactive plan for the future is the heart of the program.
Survivors of young-onset breast cancer face a significantly higher risk of developing ovarian cancer as they age if they carry specific genetic mutations. Why is this demographic a priority for retrospective screening, and how does this knowledge change their long-term surveillance?
This group is a priority because the clinical stakes are exceptionally high for women who carry BRCA1 or BRCA2 mutations. As these survivors age, their risk for ovarian cancer increases dramatically, and without genetic knowledge, they might miss the window for life-saving interventions. By identifying these carriers retrospectively, we can shift their surveillance from routine breast check-ups to aggressive ovarian cancer monitoring or preventative bilateral salpingo-oophorectomy. It is a profound clinical pivot that changes a patient’s identity from a breast cancer survivor to someone proactively managing a known genetic risk. This shift ensures that the survival they worked so hard to achieve isn’t compromised by a secondary, preventable malignancy.
Streamlined testing models often bypass traditional pre-test consultations to reduce the workload for medical staff. How does this decentralization affect the overall patient experience, and how can healthcare systems ensure that clinical expertise remains focused on the most complex cases?
The BRCA-DIRECT pathway is designed to be lean and patient-centered, removing several traditional steps like the routine pre-test consultation that used to be mandatory for everyone. This decentralization makes the process feel less like a clinical interrogation and more like a manageable part of one’s personal health routine. By automating the straightforward parts of the journey, we free up our highly skilled genetic counselors and oncologists to focus on the 10% of patients who receive a positive or complex result. These individuals require deep emotional support and nuanced clinical explanations that a standardized pamphlet cannot provide. The step-by-step beauty of this model is that it treats the patient’s time as being just as valuable as the doctor’s, ensuring that the highest level of expertise is applied where it is most desperately needed.
Automated identification using linked cancer registries allows healthcare systems to find eligible patients proactively rather than waiting for referrals. How does this transition improve resource allocation, and what impact does it have on equity for patients who might not self-advocate?
Moving toward a data-driven, automated identification system removes the “luck of the draw” that often dictates who gets tested and who doesn’t. In the past, testing relied heavily on a clinician’s memory or a patient’s own research and self-advocacy, which naturally favors those with more resources or better access to top-tier medical centers. By using linked registries, the system proactively reaches out to everyone who qualifies, regardless of their background or how long it has been since they last saw an oncologist. This is a massive step forward for health equity, as it ensures that the “hidden” survivors—those in rural areas or underserved communities—are treated with the same priority as those in urban centers. It allows us to allocate our healthcare resources based on actual clinical need rather than just who happens to walk through the door.
Expanding direct-to-patient testing to include prostate, pancreatic, and colorectal cancers is the next logical step for many health systems. What infrastructure is necessary to support this expansion, and how do you evaluate the long-term outcomes for these survivors?
To scale this to prostate, pancreatic, and colorectal cancers, we need a robust digital infrastructure that can handle the integration of national cancer registries with lab-level genetic data on a massive scale. The NHS is already commissioning a broader range of these tests, but the success will depend on our ability to track these patients over decades, not just months. We evaluate outcomes by looking at the reduction in secondary cancers and the rate at which family members are successfully screened following a positive result in a survivor. Milestones for success include achieving high participation rates across diverse cancer types and ensuring that the laboratory capacity can keep up with the influx of saliva kits. It is a logistical marathon, but the potential to save lives through early detection in these other high-risk groups is immense.
What is your forecast for the future of genetic screening in cancer survivorship?
I believe we are entering an era where genetic status will be treated as a vital sign that is updated throughout a patient’s life rather than a one-time test. In the near future, automated systems will continuously scan health records, and as new genes are discovered or testing becomes cheaper, survivors will be automatically notified if they become eligible for new screenings. We will see a shift where precision medicine is no longer a luxury for the newly diagnosed but a standard of care for the millions of survivors living their lives today. Ultimately, our goal is to ensure that the “missed opportunities” we see now become a relic of the past, replaced by a seamless, lifelong safety net of genetic vigilance.
